Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.19 AUD | -2.56% | -2.56% | +5.56% |
Apr. 23 | Microba's Revenue Climbs 297% in Fiscal Q3 | MT |
Apr. 10 | Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.56% | 56.42M | - | ||
-23.07% | 7.86B | B+ | ||
+68.36% | 4.32B | C+ | ||
+1.88% | 2.63B | B- | ||
-8.06% | 2.5B | - | ||
-41.95% | 2.33B | B- | ||
-11.99% | 1.82B | C- | ||
-21.18% | 1.51B | A- | ||
+17.44% | 1.22B | B+ | ||
-43.89% | 1.14B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MAP Stock
- Ratings Microba Life Sciences Limited